HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

USP Sounds Alarm As Delta-8 THC Noise Grows Louder In US Hemp Ingredients Market

Executive Summary

On same day USP published report on delta-8 THC, former FDA executive who led a marijuana policy working group while there advised that banishing the ingredient won’t come any easier than controlling the use of hemp ingredients in non-drug products subject to the agency’s regulatory oversight.

You may also be interested in...



First US Warnings On Drug Claims By Delta-8 THC Supplements Also Describe Safety Concerns

Announcement and warnings, in addition to noting firms’ violative drug and disease claims, explain differences between delta-8 THC and other hemp-derived cannabinoids intended for de-scheduling as controlled substances in 2018 farm bill.

Emerging US Cannabinoid Market Sales Driver Could Drive Lawful Use Legislation Off The Rails

Delta-8 THC is a close chemical cousin to the substance recognized for intoxicating effects. Its effects aren't a settled question, along with whether it meets definition of hemp stated in 2018 farm bill.

Proposed OTC Switch Rule Anticipates Digital World

FDA’s “Additional Condition for Nonprescription Use” proposal is all about information which won’t be printed on DFLs but will be integral to whether some switch proposals’ approval. But agency doesn’t explicitly exclude switch sponsors from assigning delivery of ACNU information to staff in stores or in online chats.

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS152007

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel